Sotatercept reduces bone morphogenetic protein signaling in patients with pulmonary arterial hypertension
A newly FDA-approved PAH drug may work through an unexpected mechanism, with blood-based biomarkers now enabling doctors to monitor whether the drug is actually engaging its target in individual patients.
This study establishes a clinically practical blood-based BMP pathway biomarker panel for target engagement monitoring in PAH clinical trials, validated in both UK and international replication cohorts. Critically, it reveals that sotatercept — recently FDA-approved for PAH — may work via a mechanism distinct from the expected BMPR2 rebalancing, suggesting the drug depletes circulating BMP9/10 rather than potentiating canonical BMPR2 signaling.
What the study was
- Study design
- Translational biomarker study with discovery cohort, international replication, and pilot clinical trial (n=9 sotatercept-treated patients)
- Population
- Patients with idiopathic and heritable pulmonary arterial hypertension (PAH) from UK National Cohort and StratosPHere 1 study
- Sample size
- 9
- Category
- Diagnostics
- Maturity
- Potentially Practice-Changing
- Journal
- Science Translational Medicine
Why it surfaced
PAH is a rare, life-limiting disease (unmet need); Sci Transl Med publication with validation in two independent cohorts; unexpected mechanistic finding for sotatercept (reduced rather than restored BMPR-II signaling) challenges the drug's presumed mechanism and has implications for biomarker-guided therapy; validated biomarker panel ready for clinical trial use.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.